News, Commentary & Events: IWIN

AMPLIFY INFLATION FIGHTER ETF

21.5457up0.0842 (0.3923%)

 as of 4:10:00pm ET 12/01/2022
  • Show article details.

    Irwin Naturals To Acquire Serenity Health

    Benzinga - 11/30/2022

    Irwin Naturals Inc. signed a binding, arms-length, agreement to acquire Serenity Health, LLC in Louisville, Kentucky, on November 25, 2022. Klee Irwin, CEO of Irwin Naturals, stated, "With each clinic we bring under the umbrella of Irwin Naturals Emergence, we take another step toward the forefront of this new approach to mental healthcare.

  • Show article details.

    Irwin Naturals THC Products To Be Available In Mississippi Cannabis Dispensaries

    Benzinga - 11/07/2022

    Irwin Naturals Inc. entered into a licensing and supply agreement with Mockingbird Cannabis, LLC to produce and distribute Irwin Naturals THC products in Mississippi. Klee Irwin, CEO of Irwin Naturals stated, "For 28 years, we have safely cared for the health of our customers, and we look forward to being the trusted friend on the shelves of Mississippi dispensaries for medical marijuana.

  • Show article details.

    Irwin Naturals THC Products Soon Available Across Michigan Cannabis Dispensaries

    Benzinga - 08/31/2022

    Irwin Naturals Inc. entered into a licensing agreement with 42 Degrees Processing LLC, through its subsidiary Irwin Naturals Cannabis, Inc., to produce and distribute Irwin Naturals THC products in Michigan.

  • Show article details.

    Amplify ETFs Launches the Amplify Natural Resources Dividend Income ETF (NYSE Arca: NDIV)

    GlobeNewswire - 08/24/2022

    Amplify ETFs announces the launch of the Amplify Natural Resources Dividend Income ETF, an index-based ETF investing in dividend-paying U.S. exchange-listed equities operating primarily in natural resource and commodity-related industries such as energy, chemicals, agriculture, metals & mining, paper products and timber.

  • Show article details.

    Entourage Health Partners With Irwin Naturals To Produce And Distribute Its Cannabis Products In Canada

    Benzinga - 08/04/2022

    Entourage Health Corp. has entered into an exclusive licensing, manufacturing and distribution agreement with Irwin Naturals Inc. . The new line of CBD and THC products to be produced under the agreement, curated by Entourage alongside Irwin's wholly owned subsidiary Irwin Naturals Cannabis, are expected to launch first on Entourage's Starseed Medicinal channel in Q4, 2022, with eventual expan...

More News:

Commentary

There is currently no third-party commentary available for this symbol.

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
Free commission offer applies to online purchases select ETFs in a Fidelity brokerage account. The sale of ETFs is subject to an activity assessment fee (from $0.01 to $0.03 per $1,000 of principal). ETFs are subject to market fluctuation and the risks of their underlying investments. ETFs are subject to management fees and other expenses. Unlike mutual funds, ETF shares are bought and sold at market price, which may be higher or lower than their NAV, and are not individually redeemed from the fund.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF’s prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock Inc., and its affiliates.

Fidelity receives compensation from the funds advisor or its affiliates in connection with a licensing agreement to utilize Fidelity’s active ETF methodology which may create incentives for FBS to encourage the purchase of certain ETFs.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

© 2010 Morningstar, Inc. All rights reserved. The Morningstar information contained herein (1) is proprietary to Morningstar or its affiliates; (2) may not be copied or redistributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.

462499.7.0